Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 5
Submit an article Journal homepage
671
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

Panayiotis Panayiotidisa Laikon General Hospital and National and Kapodistrian University of Athens, Athens, GreeceView further author information
,
Gayane Tumyanb N.N. Blokhin Russian Cancer Research Centre, Moscow, Russian FederationView further author information
,
Catherine Thieblemontc AP-HP, Hôpital Saint-Louis, and Université de Paris, Paris, FranceView further author information
,
Vadim V. Ptushkind City Clinical Hospital Named After S.P. Botkin, Moscow, Russian FederationView further author information
,
Ana Marin-Nieblae Hospital Universitari Vall d’Hebron, Barcelona, SpainView further author information
,
Ramon García-Sanzf Hospital Universitario de Salamanca (HUSA/IBSAL/CIBERONC), Salamanca, SpainView further author information
,
Steven Le Gouillg Service d’Hématologie Clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, FranceView further author information
,
Anastasios Stathish Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland, and Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, SwitzerlandView further author information
,
Alessia Bottosi F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
,
Habib Hamidij Genentech, Inc, South San Francisco, CA, USAView further author information
,
Pablo Katzi F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
,
Thomas Perrettii F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information
,
Jenna C. Willisk Roche Products Ltd, Welwyn Garden City, UKView further author information
&
Christian Buskel CCC Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, GermanyCorrespondence[email protected]
View further author information
 show all
Pages 1058-1069 | Received 06 Jul 2021, Accepted 02 Dec 2021, Published online: 19 Jan 2022

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.